Pharmacokinetics of ropivacaine in patients with chronic end-stage liver disease.

Background: Ropivacaine is mainly eliminated by hepatic metabolism. The authors studied the effect of chronic end-stage liver disease on the pharmacokinetics of ropivacaine.

Methods: Thirteen patients with chronic end-stage liver disease and eight healthy volunteers received a single dose of 0.

The pharmacokinetics of ropivacaine in hepatic and renal insufficiency.

In patients with chronic end-stage liver disease, the peak plasma concentrations of ropivacaine after a single intravenous ropivacaine dose are similar to those in healthy subjects. However, patients with end-stage liver disease have about a 60% lower mean ropivacaine clearance than healthy subjects and are thus expected to have over two-fold higher steady-state ropivacaine plasma concentrations during a continuous ropivacaine infusion. The peak plasma concentrations of ropivacaine after an axillary plexus block in uraemic patients are considerably higher than those in non-uraemic patients.

Effect of ciprofloxacin on the pharmacokinetics of ropivacaine.

Objective: To assess the effect of ciprofloxacin on the pharmacokinetics of ropivacaine. METHODS. In a double-blind, randomised, cross-over study, nine healthy volunteers were treated for 2.